Pharmacokinetics of the Recombinant Thrombolytic Agents: What is the Clinical Significance of Their Different Pharmacokinetic Parameters?

By Cohen A.  

BioDrugs, Vol. 11, Iss. 2, 1999-02 ,pp. : 115-123

Adis International

Access to resources Recommend Favorite

Development of Pegylated Interferons for the Treatment of Chronic Hepatitis C

By Kozlowski A.   Charles S.A.   Harris J.M.  

BioDrugs, Vol. 15, Iss. 7, 2001-07 ,pp. : 419-429

Adis International

Access to resources Recommend Favorite

Practical Communications

By Lewis-Hunstiger Marty  

Creative Nursing, Vol. 13, Iss. 3, 2007-09 ,pp. : 3-3

Springer Publishing Company

Access to resources Recommend Favorite

Leucocyte Interferon-alpha for Patients with Chronic Hepatitis C Intolerant to Other alpha-Interferons

By Tripi S.   Soresi M.   Gaetano G.D.   Carroccio A.   Giannitrapani L.   Vuturo O.   Giovanni G.D.   Montalto G.  

BioDrugs, Vol. 17, Iss. 3, 2003-01 ,pp. : 201-205

Adis International

Access to resources Recommend Favorite

The Therapeutic Potential of Intracellular Antibodies

By Pumphrey C.Y.   Marasco W.A.  

BioDrugs, Vol. 9, Iss. 3, 1998-03 ,pp. : 179-185

Adis International

Access to resources Recommend Favorite